• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

加速度计作为多发性硬化症行走行为的测量手段。

Accelerometry as a measure of walking behavior in multiple sclerosis.

机构信息

Department of Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL, USA.

出版信息

Acta Neurol Scand. 2013 Jun;127(6):384-90. doi: 10.1111/ane.12036. Epub 2012 Dec 13.

DOI:10.1111/ane.12036
PMID:23240822
Abstract

OBJECTIVE

Accelerometry has been identified as a possible ecologically valid and objective approach for measuring community ambulation in multiple sclerosis (MS). This study provides a validation of accelerometer output based on associations with Expanded Disability Status Scale (EDSS), Patient Determined Disease Steps (PDDS) Scale, and Multiple Sclerosis Walking Scale-12 (MSWS-12) scores, timed 25-foot walk (T25FW) and 6-min walk (6MW) performance, oxygen cost (O(2) cost) of walking, and spatial and temporal parameters of gait.

MATERIALS AND METHODS

256 persons with MS completed the PDDS and MSWS-12, underwent an examination for the generation of an EDSS score, undertook two T25FW tests and a 6MW while wearing a portable metabolic unit for measuring the O(2) cost of walking, completed two trials of comfortable walking on a GAITRite electronic walkway for measuring spatial and temporal parameters of gait, and then wore an Actigraph accelerometer during the waking hours of a 7-day period.

RESULTS

The accelerometer output was significantly correlated with EDSS (ρ = -0.522), PDDS (ρ = -0.551), and MSWS-12 (ρ = -0.617) scores, T25FW (ρ = -0.595) and 6MW (ρ = 0.630) performance, and O(2) cost of walking (ρ = -0.457). Regarding gait parameters, the accelerometer output was significantly correlated with velocity (ρ = 0.420), cadence (ρ = 0.349), step time (ρ = -0.353), step length (ρ = 0.395), double support (ρ = -0.424), and single support (ρ = 0.400).

CONCLUSION

We provide comprehensive evidence from a large sample of persons with MS that further supports accelerometry as a measure of walking behavior.

摘要

目的

加速度计已被确定为一种可能的生态有效且客观的方法,可用于测量多发性硬化症(MS)中的社区步行能力。本研究基于与扩展残疾状况量表(EDSS)、患者确定的疾病步骤量表(PDDS)和多发性硬化症步行量表-12(MSWS-12)评分、定时 25 英尺步行(T25FW)和 6 分钟步行(6MW)表现、步行的耗氧量(O(2)消耗)以及步态的时空参数的关联,对加速度计输出进行了验证。

材料和方法

256 名多发性硬化症患者完成了 PDDS 和 MSWS-12,进行了 EDSS 评分生成检查,穿着便携式代谢装置进行了两次 T25FW 测试和 6MW,以测量步行的 O(2)消耗,完成了两次在 GAITRite 电子步道上舒适行走的试验,以测量步态的时空参数,然后在 7 天的清醒时间内佩戴 Actigraph 加速度计。

结果

加速度计输出与 EDSS(ρ=-0.522)、PDDS(ρ=-0.551)和 MSWS-12(ρ=-0.617)评分、T25FW(ρ=-0.595)和 6MW(ρ=0.630)表现以及步行的 O(2)消耗(ρ=-0.457)呈显著相关。关于步态参数,加速度计输出与速度(ρ=0.420)、步频(ρ=0.349)、步时(ρ=-0.353)、步长(ρ=0.395)、双支撑(ρ=-0.424)和单支撑(ρ=0.400)呈显著相关。

结论

我们从大量多发性硬化症患者中提供了综合证据,进一步支持了加速度计作为行走行为测量的方法。

相似文献

1
Accelerometry as a measure of walking behavior in multiple sclerosis.加速度计作为多发性硬化症行走行为的测量手段。
Acta Neurol Scand. 2013 Jun;127(6):384-90. doi: 10.1111/ane.12036. Epub 2012 Dec 13.
2
Comparison of patient-reported outcomes of physical activity and accelerometry in people with multiple sclerosis and ambulatory impairment: A cross-sectional study.多发性硬化症伴活动障碍患者身体活动和加速度计患者报告结局的比较:一项横断面研究。
Mult Scler Relat Disord. 2024 May;85:105532. doi: 10.1016/j.msard.2024.105532. Epub 2024 Mar 1.
3
Japanese translation and validation of the 12-item Multiple Sclerosis Walking Scale version 2.12 项多发性硬化症步行量表第 2 版的日译及验证。
Mult Scler Relat Disord. 2024 Sep;89:105768. doi: 10.1016/j.msard.2024.105768. Epub 2024 Jul 11.
4
Validation of scores from a telephone administered multiple sclerosis walking scale-12 in persons with multiple sclerosis.电话管理多发性硬化行走量表 12 评分在多发性硬化症患者中的验证。
Mult Scler Relat Disord. 2024 Aug;88:105715. doi: 10.1016/j.msard.2024.105715. Epub 2024 Jun 9.
5
Accelerometry and its association with objective markers of walking limitations in ambulatory adults with multiple sclerosis.加速计及其与多发性硬化症步行受限的客观标志物在活动成年人中的关联。
Arch Phys Med Rehabil. 2010 Dec;91(12):1942-7. doi: 10.1016/j.apmr.2010.08.011.
6
Cognitive processing speed has minimal influence on the construct validity of Multiple Sclerosis Walking Scale-12 scores.认知加工速度对多发性硬化症步行量表 12 评分的结构效度影响很小。
J Neurol Sci. 2013 Dec 15;335(1-2):169-73. doi: 10.1016/j.jns.2013.09.024. Epub 2013 Sep 24.
7
Middle-range scores from the patient determined disease steps scale reflect varying levels of walking dysfunction in multiple sclerosis.从中程评分来看,患者确定疾病步骤量表反映了多发性硬化症患者在行走功能障碍方面存在不同程度的差异。
BMC Neurol. 2024 Oct 10;24(1):383. doi: 10.1186/s12883-024-03871-1.
8
Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis.多发性硬化症患者自我确定疾病阶段(PDDS)量表评分的验证
BMC Neurol. 2013 Apr 25;13:37. doi: 10.1186/1471-2377-13-37.
9
Quantifying gait impairment in multiple sclerosis using GAITRite technology.使用 GAITRite 技术定量评估多发性硬化症患者的步态障碍。
Gait Posture. 2011 May;34(1):145-7. doi: 10.1016/j.gaitpost.2011.03.020. Epub 2011 Apr 30.
10
Validation of the Brazilian version of the patient-determined disease steps scale in persons with multiple sclerosis.验证多发性硬化症患者使用的患者确定疾病步骤量表的巴西版本。
Mult Scler Relat Disord. 2019 May;30:208-214. doi: 10.1016/j.msard.2019.02.022. Epub 2019 Feb 22.

引用本文的文献

1
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT.自体造血干细胞移植治疗多发性硬化症和视神经脊髓炎谱系障碍——ECTRIMS和EBMT的建议
Nat Rev Neurol. 2025 Mar;21(3):140-158. doi: 10.1038/s41582-024-01050-x. Epub 2025 Jan 15.
2
Optimizing Detection and Prediction of Cognitive Function in Multiple Sclerosis With Ambulatory Cognitive Tests: Protocol for the Longitudinal Observational CogDetect-MS Study.使用移动认知测试优化多发性硬化症认知功能的检测和预测:纵向观察性 CogDetect-MS 研究方案。
JMIR Res Protoc. 2024 Sep 26;13:e59876. doi: 10.2196/59876.
3
Digital Technology Enablers of Tele-Neurorehabilitation in Pre- and Post-COVID-19 Pandemic Era - A Scoping Review.
新冠疫情前后远程神经康复的数字技术推动因素——一项范围综述
Int J Telerehabil. 2024 Jun 28;16(1):e6611. doi: 10.5195/ijt.2024.6611. eCollection 2024.
4
The relationship between sleep quality and gait in people with multiple sclerosis: A pilot study.多发性硬化症患者睡眠质量与步态之间的关系:一项初步研究。
Hong Kong Physiother J. 2024 Jun;44(1):11-19. doi: 10.1142/S1013702523500129. Epub 2023 May 19.
5
Translation and validation of the multiple sclerosis walking scale 12 for the German population - the MSWS-12/D.德国人群多发性硬化症步行量表12(MSWS-12/D)的翻译与验证
Health Qual Life Outcomes. 2023 Oct 9;21(1):110. doi: 10.1186/s12955-023-02190-2.
6
Wearable Sensor Technologies to Assess Motor Functions in People With Multiple Sclerosis: Systematic Scoping Review and Perspective.可穿戴传感器技术评估多发性硬化症患者的运动功能:系统综述和展望。
J Med Internet Res. 2023 Jul 27;25:e44428. doi: 10.2196/44428.
7
A Systematic Review of the Validity and Reliability of the Patient-Determined Disease Steps Scale.患者确定疾病阶段量表有效性和可靠性的系统评价
Int J MS Care. 2023 Jan-Feb;25(1):20-25. doi: 10.7224/1537-2073.2021-102. Epub 2022 Jul 5.
8
Methodological heterogeneity biases physical activity metrics derived from the Actigraph GT3X in multiple sclerosis: A rapid review and comparative study.方法学异质性对多发性硬化症中源自Actigraph GT3X的身体活动指标产生偏差:一项快速综述与比较研究。
Front Rehabil Sci. 2022 Nov 28;3:989658. doi: 10.3389/fresc.2022.989658. eCollection 2022.
9
Gait Variability to Phenotype Common Orthopedic Gait Impairments Using Wearable Sensors.使用可穿戴传感器对常见骨科步态障碍进行步态变异性与表型分析。
Sensors (Basel). 2022 Nov 29;22(23):9301. doi: 10.3390/s22239301.
10
Muscle architecture and its relationship with lower extremity muscle strength in multiple sclerosis.多发性硬化症中的肌肉结构及其与下肢肌肉力量的关系。
Acta Neurol Belg. 2022 Dec;122(6):1521-1528. doi: 10.1007/s13760-021-01768-1. Epub 2021 Aug 20.